Catalyst Pharm Inc
(NQ:
CPRX
)
19.91
-0.06 (-0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback
January 25, 2023
Catalyst is adding to its portfolio with a $160 million deal.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
January 25, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
January 25, 2023
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Via
MarketBeat
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
January 23, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The...
Via
Benzinga
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
January 23, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
$1000 Invested In This Stock 10 Years Ago Would Be Worth $27,000 Today
January 23, 2023
Via
Benzinga
Analyst Expectations for Catalyst Pharmaceuticals's Future
January 19, 2023
Via
Benzinga
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 23, 2023
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its...
Via
Benzinga
Dow, Nasdaq Boasting Triple-Digit Midday Lead
January 23, 2023
Investors seem intent on leaving last week's losses behind, as earnings season heats up.
Via
Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
January 23, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
December 21, 2022
Via
Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
December 15, 2022
Via
Benzinga
Dow Jumps Over 300 Points; Crude Oil Up 1%
January 23, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500...
Via
Benzinga
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
January 23, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product
January 23, 2023
Via
Benzinga
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views
January 23, 2023
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.
Via
Benzinga
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
January 23, 2023
Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone.
Via
Investor's Business Daily
Why Catalyst Pharmaceuticals Shares Are Moving
January 23, 2023
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13.46% to $18.00 Monday morning after Teva Pharmaceuticals stated it plans to sell a generic version of Catalyst's FIRDAPSE in...
Via
Benzinga
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
January 23, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Biotechs Making Waves With A Single Product in their Pipeline
January 11, 2023
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
Via
MarketBeat
IDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
January 09, 2023
IDEXX Laboratories sees its Relative Strength Rating reach the 80-plus level.
Via
Investor's Business Daily
Top Picks For 2023: Catalyst Pharmaceuticals - Sunday, Jan. 8
January 08, 2023
For a growth-oriented choice for the new year, I'm going with under-the-radar company, Catalyst Pharmaceuticals. Let's take a look at the company's fundamentals, technicals, and institutional support...
Via
Talk Markets
Top Picks For 2023: Catalyst Pharmaceuticals
January 02, 2023
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...
Via
Talk Markets
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Via
Benzinga
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
December 19, 2022
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's
December 16, 2022
It's practically printing cash, and even more is on the way.
Via
The Motley Fool
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
December 14, 2022
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.
Via
Investor's Business Daily
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
November 22, 2022
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
November 11, 2022
Bitcoin hit a two-year low while Meta and Tesla were in focus.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.